Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   October 2012
 
A LA UNE
09/04/2012 - Lyonbiopole / Alsace BioValley and CQDM launch a France-Quebec call for projects

Under the joint program, Lyonbiopole, Alsace BioValley and Quebec Consortium for Drug Discovery (CQDM), launch of a France-Québec call for projects. This call aims to support the development of new technologies and processes with the objective of facilitating discovery and development of new drugs. Moreover, in the context of this call, the three partners will organize a France-Quebec networking event on November 15th and 16th in Lyon.
Contact: Sarah Crochon - Innovation Project Manager - Sepsis Program: sarah.crochon@lyonbiopole.com

Learn more


10/12/2012 - 6th edition of Lyonbiopole Partnering Days : a great success for the 15 thematic roundtables

This Lyonbiopole's annual meeting is a privileged place for exchanges between all our members involved in the fight against infectious diseases and cancers. Gathering more than 200 participants (36% SMBs, 34% academics, 16% industrials and 14% partners), the 6th edition was held on October 12th, 2012 at the Congress Center WTC in Grenoble. This event has put forward the scientific, medical and economic benefits of the 119 collaborative R&D projects,  accredited by Lyonbiopole and funded since 2005. The day before, a press conference organized by Lyonbiopole highlighted these results in the presence of 5 project leaders.
Contact : Claudia Chagneau, R&D Project manager- claudia.chagneau@lyonbiopole.com

Learn more


12/07/2012 - SAVE THE DATE: 4th edition of the Lyonbiopole’s Private Inv€stment Day, on Friday December 7th, 2012

For the 4th time, Lyonbiopole organizes, in partnership wirh CREALYS, GRAIN, NOVACITE and OSEO, and with the support of Sanofi Pasteur, the Private Inv€stment Day on next Friday, December 7th 2012, from 8.30 am to 3.00 pm at the Sanofi Pasteur's Headquarters (Lyon, Gerland). This event, dedicated to SMBs and private investors aims to foster interactions between companies, new entrepreneurs and investors of every kind. This day will be organized around moments of networking (roundtables, testimony and breaks) and company and project presentations.
Contact: Isabelle Scarabin, Economic and International Affairs Director -  isabelle.scarabin@lyonbiopole.com
You want to present your company or your company project, please contact: Kevin Romani, International Project Manager - kevin.romani@lyonbiopole.com

Learn more



ZOOM SUR
PX'THERAPEUTICS

 PX’Therapeutics, located in Grenoble and Lyon (France), offers early stage research and GMP manufacturing contracts focusing on the development of protein therapeutics, monoclonal antibodies, cell therapy products and recombinant vaccines. Today, PX’Therapeutics’ strategy is to increase its manufacturing capabilities to help further our customers for clinical phase III and market production. For this purpose, we have chosen to be helped by an industrial partner, Aguettant, a French pharmaceutical group which, by investing in PX’Therapeutics, aims at diversifying its activity in the biotech sector.

Learn more



A LA UNE
From 10/21 to 10/25/2012 - First trade mission in China: Lyonbiopole come with SMBs' members in Shanghai

With the support from the Rhone-Alpes regional Council, Lyonbiopole organizes a mission in China from October, 21st to 25th, 2012, in partnership with ERAI. 4 SMBs, members of Lyonbiopole take part of this trade mission: ADOCIA, GENOWAY, METABOLYS and TRANSCURE BIOSCIENCES. It aims to introduce the health Chinese market to Rhone-Alpes’ SMBs to establish contacts with potential partners and develop their business.

Learn more


12/13/2012 - SAVE THE DATE: 4th edition of Nosocomial Infections day

For this 4th edition, Lyonbiopole and Finovi Foundation, in partnership with SHAM (insurance and risks management / health and medical-social sector), organize a conferences dealing with the hot topic of nosocomial infections. This event will take place on December 13th 2012, at the "Institut Français de l’Education" (19 allée de Fontenay 69007 Lyon) and will address "Nosocomial Pathogenesis".
Contact: Sarah Crochon, Innovation Project Manager - Sepsis program -
sarah.crochon@lyonbiopole.com

11/06/2012 – Lyonbiopole and the CEBR gather in Lyon their European cluster partners

Lyonbiopole co-organizes with the CEBR (Council of European Bio Regions) a meeting on the theme of "European Cluster Assessment" on Tuesday, November 6th at its headquarters. Lyonbiopole joined the CEBR Steering Committee in December 2011, and is the only French representative. This network of some sixty of European clusters working in the field of Health, gathers its members under “Special Interest Group” on common key topics and thus exchange good practices. The purpose of this meeting in Lyon will be to discuss the existing various methods of cluster assessment at national and European levels and work on indicators dedicated to the health sector. Contact: Isabelle Scarabin, Economic and International Affairs Director - isabelle.scarabin@lyonbiopole.com

Learn more


From 03/24/2013 to 03/26/2013 - Lyonbiopole invites you at BioVision, the World Life Sciences Forum, in Lyon

The 8th edition of BioVision will be held from 24 to 26 March 2013 in Lyon, gathering representatives of civil society, scientists, industry and policy makers to discuss key global issues of health, food and environment. The Forum will provide a new organization around three moments: the scientific conferences, BioVision Catalyzer to promote collaborative projects and BioVision Investor Conference to favour meetings between Biotech, Pharma and private and public investors.
For more information: Isabelle Scarabin, Economic and International Affairs Director - isabelle.scarabin@lyonbiopole.com
To present a project at BioVision Catalyzer : Sarah Crochon, Innovation Project Manager -  sarah.crochon@lyonbiopole.com

Learn more


11/29/2012 - Accinov invites you to participate to the event organized by Merck Millipore: "Develop Faster, industrialize quicker: solutions for your biomolecules"

As a speaker of this event, Accinov is pleased to inform you that Merck Millipore will hold a seminar at the French Institute for Education of Lyon. Entitled "Develop Faster, industrialize quicker: solutions for your biomolecules", the focus is set on biomanufacturing strategies and equipment. The participation of Pierre Fabre Immunology Center, of the CEOs of Antitope and GTP Technology and a group of experts from Merck Millipore promises interactive and fruitful discussions.
Register now and find the agenda of the day on Merck Millipore website and join Accinov during this event scheduled on 29th November at The French Institute for Education of Lyon.

Learn more



AGENDA
FABS,
October 25th to 26th 2012, Nice - France
International Sepsis Forum,
November 7th to 9th 2012, Paris - France
4th edition of ECCP,
November 11th 2012, Hambourg - Germany
BIO-Europe®,
November 12th to 14th 2012, Hamburg - Germany
4th edition of Private Inv€stment Day,
Friday december 7th, 2012, Sanofi Pasteur headquarter, Lyon Gerland - France
4th edition Nosocomial Infections Days
December 13th, 2012, Lyon - France
8th edition of BioVision World Life Sciences Forum
March 24th and 26th, 2013, Lyon - France
BIO Chicago 2013,
April 22th to 25th 2013, Chicago (IL) - USA
 
A LA UNE
10/16/2012 – 10th Eurostars call for projects is open

The 10th Eurostars call for projects is open. This European program aims at funding collaborative projects of European innovative SMBs of all technological sectors. Deadline for application is planned on April 4th 2013. Lyonbiopole can support you to build your EU project thanks to its PPTE program.
Contact: Emilie Romeo, Project Manager – emilie.romeo@lyonbiopole.com

Learn more


10/16/2012 – FP7: last funding opportunities

Several funding opportunities for your projects are still available in the FP7 before the end of the program; in 2013, any call for project will be published. Thus, multiple calls are currently open as FP7 Cooperation on "ICT, Information and Communication Technologies", "NMP Nano Nanosciences, nanotechnologies, materials and new production technologies', FP7 Capacities" Research for SMEs”, submission deadlines are on mid-November 2012. Several FP7 People calls like Marie Curie fellowships are open until January 2013. We remind you that Lyonbiopole can support you thanks to its PPTE program and help you to answer these calls.
Contact: Emilie Romeo, Project Manager – emilie.romeo@lyonbiopole.com

Learn more


10/16/2012 – 8th IMI call for project soon open

The IMI Program will soon launch its 8th call for projects. 2 topics will be linked to the “Anti-Microbial Resistance” and 4 new other topics will be dealt with: « Development of drug-drug combinations », « Developing an aetiological based taxonomy of human disease », « Building a European bank to hold and supply iPS stem cells », « Developing combination therapies ». The deadline for submission would be at the end of November 2012. Lyonbiopole can support you to build your EU project thanks to its PPTE program.
Contact: Emilie Romeo, Project Manager - emilie.romeo@lyonbiopole.com

Learn more


03/23/2012 - Reminder: 2nd Structuring Research and Development Projects of competitiveness cluster (PSPC) call for projects is open

Under the program "Investments for the future", the second call for projects "for structuring R&D projects for clusters" (AAP PSPC) is continuously open until 15 January 2013 on the site www.competitivite.gouv.fr.
To be eligible to the call, your project must be a R&D collaborative project, accredited by a French cluster, involving at least 2 companies and one lab (€ 5M expenses minimum). Lyonbiopole helps you to study your accreditation request.
Contact: Claudia Chagneau, R&D project manager - claudia.chagneau@lyonbiopole.com

Learn more



A LA UNE
06/07/2012 - Renewal of "Companies" college and "Competence Centers" college of non-permanent Administrators of Lyonbiopole for 2012-2014

The Lyonbiopole's Board of Directors is composed of 6 permanent Administrators representing Founding Members - bioMérieux, Merial, Sanofi Pasteur, Becton Dickinson France, Fondation Mérieux, Commissariat à l'Energie Atomique (CEA) - and 4 others non permanent Administrators. These are elected and re-elected for a term of two years. Thus, the General Assembly of Lyonbiopole on June 7th, 2012 was elected to the "SMB" College: Edelris replacing Alizé Pharma and renewed ImmunID Technologies. From the "Competence Centers" college side, AVIESAN was renewed with the presence of the CNRS Regional Delegate and the Lyon Civil Hospitals joined the Lyonbiopole's Board of Directors.

Learn more


11/2012 - Accinov is preparing a call for expressions of interest to support the development of enabling technologies for biomanufacturing

Just six months after starting-up BioMaTools, Accinov’s program to promote and support innovation in biomanufacturing, the association is aiming at concretizing its initiative. To do so, the preparation of a call for expressions of interest is on-going. The purpose is to set up a Rhone-Alpes-based multidisciplinary network dedicated to biomanufacturing technologies and to foster the development of innovative equipment.
The call will be issued in the next weeks and the deadline for applications will be in December.
Contact: Sylvain Peyrache, in charge of BioMaTools program - sylvain.peyrache@accinov.com

10/22/2012 - Adocia is extending its intellectual property to new formulations of monoclonal antibodies

Adocia, member of Lyonbiopole specialized in the formulation of therapeutic proteins for the treatment of diabetes and chronic wounds, announces today that it has filed another three patent applications covering new formulations of monoclonal antibodies. These patents cover innovative formulations of monoclonal antibodies enabling a subcutaneous injection, in order to improve patients’ lives and reduce treatment costs.

Learn more


10/11/2012 - Fab'entech launches a Phase I clinical trial in Singapore for its new product against H5N1 Avian Influenza
 

Fab'entech, member of Lyonbiopole and specialized in developing specific polyclonal immunoglobulins against emerging infectious diseases announces that the company is launching its first clinical trial in humans for its product against the H5N1 Avian Influenza virus. If promising results from animal testing are confirmed, these immunoglobulins may provide a new specific approach for the treatment of subjects infected by or exposed to the H5N1 virus.

Learn more


09/17/2012 - Jennerex and Transgene Present Positive Clinical Data from Phase 2 Trial of JX594/TG6006 in Sorafenib-Refractory Liver Cancer Patients

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies and Transgene, presented interim Phase 2 clinical data of JX594/TG6006 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC). The data were presented in an oral presentation at the International Liver Cancer Association (ILCA1) Annual Meeting in Berlin, Germany, by Mong Cho, M.D., from Pusan National University Yangsan Hospital, South Korea.

Learn more


09/11/2012 - Sanofi Pasteur announces publication in the Lancet of world's
first efficacy results for its dengue vaccine candidate

Sanofi Pasteur, the vaccines division of Sanofi, announced today the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |